Related Experiment Video
Updated: May 31, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[Ischemic stroke and heparin-induced thrombocytopenia]
Haruko Yamamoto1, Shigeki Miyata
1Department of Advanced Medical Technology Development, Research and Development Initiative Center.
Immune-mediated heparin-induced thrombocytopenia (HIT) affects acute ischemic stroke patients treated with unfractionated heparin. Early HIT diagnosis and treatment are crucial for better outcomes in stroke patients.
Area of Science:
- Neurology
- Hematology
- Pharmacology
Context:
- Immune-mediated heparin-induced thrombocytopenia (HIT) is a rare but serious complication of heparin therapy.
- HIT can lead to severe thromboembolic events, high mortality, and morbidity.
- Limited data exist on HIT prevalence in acute ischemic stroke patients.
Purpose:
- To estimate the prevalence of HIT in acute ischemic stroke patients receiving unfractionated heparin.
- To highlight the importance of prompt HIT diagnosis and treatment in stroke management.
Summary:
- A retrospective study estimated HIT prevalence at 0.5%, while a multi-center prospective cohort study found it to be 1.7% in unfractionated heparin-treated acute ischemic stroke patients.
- Delayed HIT treatment is associated with poor outcomes.
- Increased heparin use in stroke care necessitates heightened awareness of HIT.
Impact:
- Findings underscore the need for stroke physicians to be vigilant for HIT.
- Prompt recognition and management of HIT can improve patient outcomes.
- This research contributes to understanding HIT's clinical significance in acute ischemic stroke.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Ischemic Stroke l: Introduction
Venous Thrombosis III: Interprofessional Care
Transient Ischemic Attack l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction

